Qian Li

Dr. Qian Li


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2023 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
ZCZhisheng Chen
Zhisheng Chen
MCMengxin Chen
Mengxin Chen
PZPing Zeng
Ping Zeng
XYXiaobo Yang
Xiaobo Yang
QLQian Li
Qian Li
Studies on aspirin’s effects on metabolic-associated fatty liver disease (MAFLD) are limited. The aim of this study was to assess the association between aspirin and all-cause and cardiovascular di...

11 July 2018 in Trials
Verified
Journal Article
Open access
QLQian Li
Qian Li
BZBeiping Zhang
Beiping Zhang
SHShaogang Huang
Shaogang Huang
WOWenwei Ouyang
Wenwei Ouyang
JXJian-Hui Xie
Jian-Hui Xie
XYXiao-Bo Yang
Xiao-Bo Yang
Background: Irritable bowel syndrome (IBS) is a chronic, recurring condition, prevalent in the general population. Current medication treatments usually leave patients undertreated. Nowadays, Chinese medicine (CM) is being considered as a promising treatment approach for IBS. However, due to methodological limitations, there is no strong evidence to support CM. Although IBS relapses are common, the relapse assessment has always been neglected in CM study designs. Meanwhile, in clinical practice and studies, it has been found that certain CM formulas can only benefit certain kinds of patients. Discovering what population and illness characteristics likely respond to outcomes may help improve the effectiveness of CM. The aims of this study are to evaluate the efficacy and safety of Tiao-Chang Ke-Min (TCKM) granules for IBS, especially in reducing IBS symptoms' relapse, by a highquality randomized controlled trial and then to optimize the indication of the TCKM granules. Methods/design: This is a parallel-group, randomized, double-blind, placebo-controlled trial embedded with outcome predictive factors. Eligible patients with diarrhea-predominant IBS will be randomized into either a TCKM granule group or a placebo group. Patients from both groups will receive health education. The treatment duration is 4 weeks and the follow-up is 12 weeks. The primary outcome is global improvement measured with adequate relief (AR). The second outcome measures include time until relief, time until first relapse, total relapse times, long-term effectiveness, individual symptoms, IBS-Symptom Severity Score (IBS-SSS), IBS-Quality of Life Questionnaire (IBS-QOL), and Hospital Anxiety and Depression Scale (HADS). Predictive factors associated with patient and illness characteristics have been widely collected. These factors will be embedded in this trial for further identification. Discussion: This trial may provide high-quality evidence on the efficacy and safety of TCKM granules for IBS and a more accurate indication. Importantly, this trial will provide a new research method for improving the therapeutic effects of CM for clinicians and researchers. To address IBS relapse assessment, a series of special definitions of relapse incidents has been made for this trial.

17 April 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZSZhikai Su
Zhikai Su
ZLZhenjie Ling
Zhenjie Ling
HCHaoqiang Chen
Haoqiang Chen
LHLei Hu
Lei Hu
SXSongtao Xiang
Songtao Xiang
JZJianfu Zhou
Jianfu Zhou
Objective: Evidence suggests that nephrolithiasis and hyperlipidemia are linked. The study is designed to identify diagnostic biomarkers for nephrolithiasis in conjunction with hyperlipidemia using bioinformatics analysis, while exploring the potential common denominator pathogenesis. Methods: The NCBI Gene Expression Omnibus (GEO) database provided separate datasets for nephrolithiasis and hyperlipidemia. We employed the R limma package to detect differentially expressed genes (DEGs), which were subsequently analyzed for enrichment using Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Immune cell infiltration was analyzed by the CIBERSORT method. The WGCNA-R package clustered genes with similar expression profiles, followed by an analysis of the associations between the modules and specific traits or phenotypes. The STRING database was utilized to establish a protein-protein interaction (PPI) network and key functional modules, which were then analyzed using Cytoscape software. Diagnostic genes for both diseases were screened from core hub genes using least absolute shrinkage and selection operator (Lasso) regression. Subsequently, we generated receiver operating characteristic (ROC) curves to validate the predictive ability of these diagnostic genes for diagnosing nephrolithiasis in combination with hyperlipidemia. Lastly, the Network Analyst platform facilitated the construction of transcription factor-gene (TF-gene) and TF-miRNA regulatory networks. Results: Based on datasets of nephrolithiasis and hyperlipidemia, we identified 167 DEGs and 74 hub genes through WGCNA. Using PPI networks and machine learning techniques, we recognized three frequently diagnostic genes (HSP90AB1, HSPA5, and STUB1), which demonstrated high diagnostic validity. The functional enrichment of these three diagnostic genes primarily involved pathways related to cellular metabolism. Conclusions: Our study identified three candidate diagnostic genes that can predict nephrolithiasis in conjunction with hyperlipidemia, providing a solid foundation for further exploration into the pathogenesis of nephrolithiasis and hyperlipidemia.

1 December 2025 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
JMJia-Hao Mo
Jia-Hao Mo
PZPing Zeng
Ping Zeng
LZLi-Lei Zhou
Li-Lei Zhou
BXBing-Qing Xia
Bing-Qing Xia
XYXiao-Bo Yang
Xiao-Bo Yang
QLQian Li
Qian Li
Irritable bowel syndrome (IBS) is one of the most common gut-brain interaction disorders. Most current IBS randomized controlled trials (RCTs) do not justi